Table 3.
Peptide-transitions significantly associated with urban–rural environment at birth
| Protein | Peptide | Controls | Psychosis | |||
|---|---|---|---|---|---|---|
| Fold-change | P | Corrected P | Fold-change | One-sided P | ||
| Serum albumin (ALBU) | ETYGEMADCCAK | 3.220 | 3.79E−29 | 3.15E−27 | 4.050 | 7.29E−10 |
| Plasma kallikrein (KLKB1) | LSMDGSPTR | 1.497 | 7.85E−13 | 6.52E−11 | 1.818 | 1.19E−06 |
| Zinc-alpha-2-glycoprotein (ZA2G) | AGEVQEPELR | −1.286 | 9.00E−11 | 7.47E−09 | −1.211 | 0.0117 |
| Apolipoprotein A-IV (APOA4) | IDQNVEELK | −1.324 | 1.32E−07 | 1.10E−05 | −1.254 | 0.0143 |
| Apolipoprotein C-I (APOC1) | EFGNTLEDK | −1.203 | 6.98E−07 | 5.79E−05 | −1.216 | 0.0147 |
| Ceruloplasmin (CERU) | EVGPTNADPVCLAK | 1.232 | 7.00E−07 | 5.81E−05 | 1.222 | 0.0129 |
| Hemopexin (HEMO) | VDGALCMEK | 1.265 | 2.21E−06 | 0.00018343 | 1.086 | 0.268 |
| Protein deglycase DJ-1 (PARK7) | DGLILTSR | −1.152 | 3.16E−06 | 0.00026228 | −1.135 | 0.0345 |
| Apolipoprotein M (APOM) | SLTSCLDSK | 1.243 | 4.23E−06 | 0.00035109 | 1.356 | 0.000394 |
| Fructose-bisphosphate aldolase A (ALDOA) | ALANSLACQGK | 1.200 | 5.98E−06 | 0.00049634 | 1.271 | 0.00479 |
| Clusterin (CLUS) | IDSLLENDR | −1.188 | 1.25E−05 | 0.0010375 | −1.233 | 0.0122 |
| C4b-binding protein alpha chain (C4BPA) | YTCLPGYVR | 1.315 | 1.40E−05 | 0.001162 | −1.015 | a |
| Apolipoprotein A-I (APOA1) | ATEHLSTLSEK | −1.189 | 2.11E−05 | 0.0017513 | −1.009 | 0.462 |
| Prothrombin (THRB) | SGIECQLWR | 1.333 | 2.35E−05 | 0.0019505 | 1.356 | 0.00339 |
| Apolipoprotein E (APOE) | AATVGSLAGQPLQER | −1.148 | 3.20E−05 | 0.002656 | −1.019 | 0.385 |
| Serum amyloid P-component (SAMP) | IVLGQEQDSYGGK | −1.214 | 5.24E−05 | 0.0043492 | −1.161 | 0.0623 |
| Alpha-1-antichymotrypsin (AACT) | EQLSLLDR | −1.188 | 9.81E−05 | 0.0081423 | −1.237 | 0.0104 |
| Protein AMBP (AMBP) | TVAACNLPIVR | 1.148 | 0.000136 | 0.011288 | 1.118 | 0.0581 |
| Protein S100-A6 (S10A6) | LQDAEIAR | −1.188 | 0.000144 | 0.011952 | −1.015 | 0.438 |
| Apolipoprotein A-II (APOA2) | SPELQAEAK | −1.199 | 0.000145 | 0.012035 | −1.06 | 0.288 |
| Ig gamma-3 chain C region (IGHG3) | NQVSLTCLVK | 1.162 | 0.00015 | 0.01245 | 1.240 | 0.00564 |
| Apolipoprotein A-IV (APOA4) | ALVQQMEQLR | −1.191 | 0.000219 | 0.018177 | −1.229 | 0.0153 |
| Antithrombin-III (ANT3) | LPGIVAEGR | −1.182 | 0.000235 | 0.019505 | −1.206 | 0.0157 |
| Phosphoglycerate kinase 1 (PGK1) | AGGFLMK | −1.127 | 0.000312 | 0.025896 | −1.074 | 0.179 |
| Alpha-1-antichymotrypsin (AACT) | EIGELYLPK | −1.162 | 0.000473 | 0.039259 | −1.218 | 0.0116 |
| Inter-alpha-trypsin inhibitor heavy chain H2 (ITIH2) | FYNQVSTPLLR | −1.128 | 0.000489 | 0.040587 | −1.090 | 0.141 |
P-values were corrected for multiple testing using the false discovery rate. The selected covariates are listed in Supplementary Table 5. aThe direction of the fold-change in psychosis patients was not consistent with that in control subjects and so a one-sided test was not conducted (two-sided P = 0.00116)